Premium
Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay
Author(s) -
Astori Cesare,
Bonfichi Maurizio,
Pagnucco Guido,
Bernasconi Paolo,
Lazzarino Mario,
Orlandi Ester,
Bernasconi Carlo
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.912908.x
Subject(s) - cd59 , erythropoietin , medicine , eculizumab , paroxysmal nocturnal hemoglobinuria , recombinant dna , decay accelerating factor , erythropoiesis , immunology , anemia , antibody , biology , complement system , biochemistry , gene
We describe a 28‐year‐old man with paroxysmal nocturnal haemoglobinuria (PNH) and a high transfusion requirement. Prior to and during therapy with recombinant human erythropoietin (rHuEpo), we evaluated the levels of ‘decay‐accelerating‐factor’, CD55, and ‘membrane‐inhibitor‐of‐reactive‐lysis’, CD59, as markers of the disease, whilst CD58, a marker present on leucocytes, was utilized to monitor normal haemopoietic activity. The patient became transfusion independent 1 month after beginning rHuEpo and remains well. The analysis of CD55, CD59 and CD58 suggests that the efficacy of rHuEpo was due to a selective rHuEpo action on normal erythroid clones.